CoChat

Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma

Shepherd, S.T.C., Kelly-Morland, C., Drage, S., Brady, A.F., Macwana, R., Pickering, L., Larkin, J., Hill, P., Turajlic, S. · 2025 · ESMO Open
Cited by 6

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.esmoop.2025.105109

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 18

  1. Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 · DOI · Paper page
  2. Maher, 1990, Clinical features and natural history of von Hippel-Lindau disease, Q J Med, 77, 1151, 10.1093/qjmed/77.2.1151 · DOI · Paper page
  3. Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J Med Genet, 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
  4. Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat Rev Cancer, 15, 55, 10.1038/nrc3844 · DOI · Paper page
  5. Zhang, 2022, Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients, J Med Genet, 59, 951, 10.1136/jmedgenet-2021-108216 · doi:10.1136/jmedgenet-2021-108216
  6. Wang, 2018, Risk factors for survival in patients with von Hippel-Lindau disease, J Med Genet, 55, 322, 10.1136/jmedgenet-2017-104995 · doi:10.1136/jmedgenet-2017-104995
  7. Kaelin, 2022, Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer, J Clin Invest, 132, 10.1172/JCI162480 · DOI · Paper page
  8. Rogers, 2013, Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor, J Med Chem, 56, 1739, 10.1021/jm301847z · DOI · Paper page
  9. Iliopoulos, 2024, Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study, Lancet Oncol, 25, 1325, 10.1016/S1470-2045(24)00389-9 · DOI · Paper page
  10. Dhawan, 2022, First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma, CNS Oncol, 11, 10.2217/cns-2022-0008 · DOI
  11. Choueiri, 2022, LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC), J Clin Oncol, 40
  12. Choueiri, 2025, Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study, Lancet Oncol, 26, 64, 10.1016/S1470-2045(24)00649-1 · DOI
  13. Choueiri, 2024, Belzutifan versus everolimus for advanced renal-cell carcinoma, N Engl J Med, 391, 710, 10.1056/NEJMoa2313906 · DOI · Paper page
  14. Trinh, 2023, FDA approval summary: belzutifan for VHL disease tumors—letter, Clin Cancer Res, 29, 10.1158/1078-0432.CCR-22-2968 · DOI
  15. Gläsker, 2005, Risk of hemorrhage in hemangioblastomas of the central nervous system, Neurosurgery, 57, 10.1227/01.NEU.0000163250.71951.18 · doi:10.1227/01.neu.0000163250.71951.18
  16. Ene, 2015, Spontaneous hemorrhage from central nervous system hemangioblastomas, World Neurosurg, 83, 1180.e13, 10.1016/j.wneu.2015.02.009 · doi:10.1016/j.wneu.2015.02.009
  17. Saeed, 2023, Fatal intracranial hemorrhage with belzutifan in von Hippel-Lindau disease-associated hemangioblastoma: a case report, JCO Precis Oncol, 7
  18. Jonasch, 2018, Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial, Lancet Oncol, 19, 1351, 10.1016/S1470-2045(18)30487-X · DOI · Paper page

Metadata

Authors
Shepherd, S. T. C., Kelly-Morland, C., Drage, S., Brady, A. F., Macwana, R., Pickering, L., Larkin, J., Hill, P., & Turajlic, S.
Venue
ESMO Open
Publisher
Elsevier BV
Published
2025-05
Volume
10
Issue
5
Pages
105109
ISSN
2059-7029
Cited by
6
References
6
Language
en
Licence
Funders
  • VHL Alliance (PRJ_20450)
  • National Institutes of Health (U01 CA247439)
  • Melanoma Research Alliance (686061)
  • National Institute for Health and Care Research
  • Wellcome Trust
  • NIHR Maudsley Biomedical Research Centre
  • Medical Research Council
  • The Francis Crick Institute
  • Institute of Cancer Research (A29911, FC10988, A109)
  • U.S. Department of Defense (W81XWH-22-1-0652)
  • Rosetrees Trust (A2204)
  • Royal Marsden Cancer Charity
  • Cancer Research UK (FC010110)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma. https://app.cochat.ai/papers/10.1016/j.esmoop.2025.105109
The paper
Shepherd, S. T. C., Kelly-Morland, C., Drage, S., Brady, A. F., Macwana, R., Pickering, L., Larkin, J., Hill, P., & Turajlic, S. (2025). Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma. ESMO Open. https://doi.org/10.1016/j.esmoop.2025.105109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.